Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease

In recent years, the incidental rate of neurodegenerative disorders has increased proportionately with the aging population. Alzheimer's disease (AD) is one of the most commonly reported neurodegenerative disorders, and it is estimated to increase by roughly 30% among the aged population. In sp...

Full description

Saved in:
Bibliographic Details
Main Authors: Govindarajan Karthivashan (Author), Palanivel Ganesan (Author), Shin-Young Park (Author), Joon-Soo Kim (Author), Dong-Kug Choi (Author)
Format: Book
Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_f711832bcc6f46b3b1cd59185da8e3dd
042 |a dc 
100 1 0 |a Govindarajan Karthivashan  |e author 
700 1 0 |a Palanivel Ganesan  |e author 
700 1 0 |a Shin-Young Park  |e author 
700 1 0 |a Joon-Soo Kim  |e author 
700 1 0 |a Dong-Kug Choi  |e author 
245 0 0 |a Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease 
260 |b Taylor & Francis Group,   |c 2018-01-01T00:00:00Z. 
500 |a 1071-7544 
500 |a 1521-0464 
500 |a 10.1080/10717544.2018.1428243 
520 |a In recent years, the incidental rate of neurodegenerative disorders has increased proportionately with the aging population. Alzheimer's disease (AD) is one of the most commonly reported neurodegenerative disorders, and it is estimated to increase by roughly 30% among the aged population. In spite of screening numerous drug candidates against various molecular targets of AD, only a few candidates - such as acetylcholinesterase inhibitors are currently utilized as an effective clinical therapy. However, targeted drug delivery of these drugs to the central nervous system (CNS) exhibits several limitations including meager solubility, low bioavailability, and reduced efficiency due to the impediments of the blood-brain barrier (BBB). Current advances in nanotechnology present opportunities to overcome such limitations in delivering active drug candidates. Nanodrug delivery systems are promising in targeting several therapeutic moieties by easing the penetration of drug molecules across the CNS and improving their bioavailability. Recently, a wide range of nano-carriers, such as polymers, emulsions, lipo-carriers, solid lipid carriers, carbon nanotubes, metal based carriers etc., have been adapted to develop successful therapeutics with sustained release and improved efficacy. Here, we discuss few recently updated nano-drug delivery applications that have been adapted in the field of AD therapeutics, and future prospects on potential molecular targets for nano-drug delivery systems. 
546 |a EN 
690 |a alzheimer's 
690 |a nanodrugs 
690 |a molecular targets 
690 |a acetylcholine 
690 |a oxidative stress 
690 |a cns 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Delivery, Vol 25, Iss 1, Pp 307-320 (2018) 
787 0 |n http://dx.doi.org/10.1080/10717544.2018.1428243 
787 0 |n https://doaj.org/toc/1071-7544 
787 0 |n https://doaj.org/toc/1521-0464 
856 4 1 |u https://doaj.org/article/f711832bcc6f46b3b1cd59185da8e3dd  |z Connect to this object online.